ClinicalTrials.gg
CompletedNCT01913314Updated Jan 7, 2019Results posted

A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants

A Phase 1 interventional study of [^14C]-LY2835219 in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This type of study is called a radiolabeled study. For this study, LY2835219 (study drug) has been specially prepared to contain radiolabeled carbon [\^14C]. [\^14C] is a naturally occurring radioactive form of the element carbon. This study will help understand how the drug appears in the blood, urine, and stool after it is administered.

In addition, this study will also evaluate the safety and tolerability of a single dose of LY2835219 when given to healthy participants. Information about any side effects that may occur will also be collected.

This study will last about 3 weeks for each participant, not including screening.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy male or female participants as determined by medical history and physical examination
  • Male participants will be sterile
  • Female participants will be surgically sterile or
  • Have a (BMI) of 18 to 29 kilograms per square meter (kg/m\^2)
  • Have venous access sufficient to allow for blood sampling

Exclusion criteria

Exclusion Criteria:

  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • Gastrointestinal disorders causing symptoms such as nausea, vomiting, and diarrhea, or malabsorption syndromes
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [^14C]-LY2835219

    Single 150 milligram (mg) oral dose solution of LY2835219 containing 5 micro-curies of (µCi) \[\^14C\] labeled drug

    Drug: [^14C]-LY2835219

Interventions

06

What researchers measure

Primary outcomes

  1. Urinary and Fecal Excretion of LY2835219-Related Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    The percentage of the total radioactive dose administered that was excreted in urine or feces = (amount of radioactive dose recovered in urine or feces / total radioactive dose administered) \* 100.

    Time frame: Predose up to Day 14 postdose; Fecal samples collected at 24-hour (h) intervals; Urine collected at 0 to 6 h, 6 to 12 h, and 12 to 24 h postdose and at 24-h intervals thereafter up to Day 14 postdose

Secondary outcomes

  1. Plasma Pharmacokinetics (PK) of LY2835219 and Metabolite of LY2835219: Maximum Observed Concentration (Cmax)

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose

  2. Plasma PK of Radioactivity: Cmax

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose

  3. Plasma PK of LY2835219, Metabolite of LY2835219, and Radioactivity: Time of Maximum Observed Concentration (Tmax)

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose

  4. Plasma PK of LY2835219 and Metabolite of LY2835219: Area Under the Concentration-Time Curve From Time Zero to the Last Time Point With a Measurable Concentration [AUC(0-tlast)]

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose

  5. Plasma PK of Radioactivity: AUC(0 to Tlast)

    The PK of radioactivity was measured as nanogram equivalents times hours per gram (ng Eq\*h/g).

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose

  6. Plasma PK of LY2835219 and Metabolite of LY2835219: Area Under the Concentration Versus Time Curve From Zero to Infinity [AUC(0-∞)]

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose

  7. Plasma PK of Radioactivity: AUC(0-∞)

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose

  8. Relative Abundance of LY2835219 and Metabolites of LY2835219 Eliminated in Urine and Feces

    The abundance (as percentage dose) of LY2835219 or its metabolites eliminated in feces is calculated as = (amount of LY2835219 or its metabolites recovered in feces / total amount administered) \* 100. Due to low radioactivity of dose recovered in urine, further quantitative profiling of urine was not conducted.

    Time frame: Predose through 216 h postdose; Fecal samples collected at 24-h intervals

  9. Relative Abundance of LY2835219 and Metabolites of LY2835219 in Plasma

    The relative abundance of LY2835219 or its metabolites in plasma were estimated based on AUC(0-∞) and reported as a percentage of total plasma radioactivity. The relative abundance of LY2835219 or its metabolites calculated as = \[AUC (0-∞) of LY2835219 or its metabolites in plasma / AUC (0-∞) of total plasma radioactivity\] \* 100.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose

07

Results

Posted Aug 7, 2018

Participant flow

Participant flow — Overall Study
Milestone[^14C]-LY2835219
Started6
Received study drug6
Completed6
Not completed0

Outcome measures

PrimaryUrinary and Fecal Excretion of LY2835219-Related Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

The percentage of the total radioactive dose administered that was excreted in urine or feces = (amount of radioactive dose recovered in urine or feces / total radioactive dose administered) \* 100.

Time frame:
Predose up to Day 14 postdose; Fecal samples collected at 24-hour (h) intervals; Urine collected at 0 to 6 h, 6 to 12 h, and 12 to 24 h postdose and at 24-h intervals thereafter up to Day 14 postdose
Reported as:
Mean · percentage radioactive dose administered
Urinary and Fecal Excretion of LY2835219-Related Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
percentage radioactive dose administered[^14C]-LY2835219
Urine3.43 ± 2.20
Feces81.0 ± 6.71
SecondaryPlasma Pharmacokinetics (PK) of LY2835219 and Metabolite of LY2835219: Maximum Observed Concentration (Cmax)
Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Plasma Pharmacokinetics (PK) of LY2835219 and Metabolite of LY2835219: Maximum Observed Concentration (Cmax)
nanograms per milliliter (ng/mL)[^14C]-LY2835219
LY283521963.7 ± 49
M2030.9 ± 19
SecondaryPlasma PK of Radioactivity: Cmax
Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Reported as:
Geometric mean · nanogram equivalents per gram (ng Eq/g)
Plasma PK of Radioactivity: Cmax
nanogram equivalents per gram (ng Eq/g)[^14C]-LY2835219
Plasma PK of Radioactivity: Cmax123 ± 27
SecondaryPlasma PK of LY2835219, Metabolite of LY2835219, and Radioactivity: Time of Maximum Observed Concentration (Tmax)
Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Reported as:
Median · h
Plasma PK of LY2835219, Metabolite of LY2835219, and Radioactivity: Time of Maximum Observed Concentration (Tmax)
h[^14C]-LY2835219
LY28352198.00 (6.00 to 8.00)
M208.00 (6.00 to 10.00)
Total Radioactivity8.00 (6.00 to 10.00)
SecondaryPlasma PK of LY2835219 and Metabolite of LY2835219: Area Under the Concentration-Time Curve From Time Zero to the Last Time Point With a Measurable Concentration [AUC(0-tlast)]
Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Reported as:
Geometric mean · nanograms*hour/milliliter (ng*h/mL)
Plasma PK of LY2835219 and Metabolite of LY2835219: Area Under the Concentration-Time Curve From Time Zero to the Last Time Point With a Measurable Concentration [AUC(0-tlast)]
nanograms*hour/milliliter (ng*h/mL)[^14C]-LY2835219
LY28352192310 ± 85
M201760 ± 43
SecondaryPlasma PK of Radioactivity: AUC(0 to Tlast)

The PK of radioactivity was measured as nanogram equivalents times hours per gram (ng Eq\*h/g).

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Reported as:
Geometric mean · ng Eq*h/g
Plasma PK of Radioactivity: AUC(0 to Tlast)
ng Eq*h/g[^14C]-LY2835219
Plasma PK of Radioactivity: AUC(0 to Tlast)6580 ± 41
SecondaryPlasma PK of LY2835219 and Metabolite of LY2835219: Area Under the Concentration Versus Time Curve From Zero to Infinity [AUC(0-∞)]
Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Reported as:
Geometric mean · ng*h/mL
Plasma PK of LY2835219 and Metabolite of LY2835219: Area Under the Concentration Versus Time Curve From Zero to Infinity [AUC(0-∞)]
ng*h/mL[^14C]-LY2835219
LY28352192370 ± 83
M201830 ± 42
SecondaryPlasma PK of Radioactivity: AUC(0-∞)
Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Reported as:
Geometric mean · ng Eq*h/g
Plasma PK of Radioactivity: AUC(0-∞)
ng Eq*h/g[^14C]-LY2835219
Plasma PK of Radioactivity: AUC(0-∞)7010 ± 42
SecondaryRelative Abundance of LY2835219 and Metabolites of LY2835219 Eliminated in Urine and Feces

The abundance (as percentage dose) of LY2835219 or its metabolites eliminated in feces is calculated as = (amount of LY2835219 or its metabolites recovered in feces / total amount administered) \* 100. Due to low radioactivity of dose recovered in urine, further quantitative profiling of urine was not conducted.

Time frame:
Predose through 216 h postdose; Fecal samples collected at 24-h intervals
Reported as:
Number · percentage of radioactive dose excreted
Relative Abundance of LY2835219 and Metabolites of LY2835219 Eliminated in Urine and Feces
percentage of radioactive dose excreted[^14C]-LY2835219
LY28352197
Metabolites52
SecondaryRelative Abundance of LY2835219 and Metabolites of LY2835219 in Plasma

The relative abundance of LY2835219 or its metabolites in plasma were estimated based on AUC(0-∞) and reported as a percentage of total plasma radioactivity. The relative abundance of LY2835219 or its metabolites calculated as = \[AUC (0-∞) of LY2835219 or its metabolites in plasma / AUC (0-∞) of total plasma radioactivity\] \* 100.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h postdose, thereafter at 24-h intervals up to Day 14 postdose
Reported as:
Number · percentage of total plasma radioactivity
Relative Abundance of LY2835219 and Metabolites of LY2835219 in Plasma
percentage of total plasma radioactivity[^14C]-LY2835219
LY283521934
Metabolites44

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
[^14C]-LY2835219—0/6 (0%)4/6 (66.7%)
Most frequent other events
Most frequent other events
Event[^14C]-LY2835219
Vessel Puncture Site HaematomaGeneral disorders2/6
Vessel Puncture Site PainGeneral disorders1/6
Vessel Puncture Site SwellingGeneral disorders1/6
FolliculitisInfections and infestations1/6
ExcoriationInjury, poisoning and procedural complications1/6
Pain in ExtremityMusculoskeletal and connective tissue disorders1/6
HeadacheNervous system disorders1/6
ChokingRespiratory, thoracic and mediastinal disorders1/6

Baseline characteristics

Participants who received study drug.

Age, Categorical
Age, Categorical(Participants)[^14C]-LY2835219
<=18 years0
Between 18 and 65 years6
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)[^14C]-LY2835219
Female3
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)[^14C]-LY2835219
Hispanic or Latino1
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)[^14C]-LY2835219
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White6
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)[^14C]-LY2835219
United States6
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madison, Wisconsin 53704, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2013
First posted
Aug 1, 2013
Start
Aug 2013
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Aug 7, 2018
Last update
Jan 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01913314
Responsible party
Sponsor
First posted
Aug 1, 2013
Start date
Aug 2013
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Aug 7, 2018
Last update
Jan 7, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion